Vanda Pharmaceuticals Inc (VNDA.OQ)
22 Jul 2014
|Market Cap (Mil.):||$451.20|
|Shares Outstanding (Mil.):||33.87|
Jan 31 - Vanda Pharmaceuticals Inc said on Friday that U.S. health regulators have approved its drug Hetlioz to regulate the internal body clocks of blind patients and help normalize sleep patterns.
- Vanda Pharmaceuticals Inc said on Friday that U.S. health regulators have approved its experimental drug to regulate the internal body clocks of blind patients and help normalize sleep patterns.
|Takeda Pharmaceutical Co Ltd (4502.T)||¥4,666||-7.00|
|Dainippon Sumitomo Pharma Co Ltd (4506.T)||¥1,219||0.00|
|Pfizer Inc. (PFE.N)||$30.49||+0.14|
|Merck & Co., Inc. (MRK.N)||$58.43||+0.43|
|Sanofi SA (SASY.PA)||€77.33||+0.34|
|AstraZeneca plc (AZN.L)||4,424.50p||-1.50|
|Eli Lilly and Co (LLY.N)||$63.72||+0.08|
Earnings vs. Estimates
Analyst Research Reports
"The Economy Matters" Report for VNDA: the economy's impact on VNDA's price and risk, featuring the powerful Economic Climate Rating
Provider: MacroRisk Analytics/EconomicInvestor
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: S&P Capital IQ Quantitative Report
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.